Navigation Links
Weight-Loss Medication Evaluated By Nutrition Expert

A 60 mg low-dose version of the prescription weight-loss medication orlistat (marketed by GlaxoSmithKline as Xenical? 120 mg) was found to be safe, effective and tolerable in overweight individuals,// according to new data presented today at the 2005 Annual Meeting of NAASO, The Obesity Society in Vancouver, British Columbia.

The study, which compared orlistat 60 mg plus diet to placebo plus diet in patients with a body mass index (BMI) of 25 to 28, demonstrates a statistically significant difference in weight loss. Orlistat patients who completed the four-month treatment period lost 5 percent of their baseline weight and diet alone lost 3.3 percent.

The randomized, placebo-controlled, 16-week study was conducted in a primary care setting, offered minimal intervention and was largely self-instructional. Approximately 36 percent of orlistat users and 28 percent of the placebo group (who used diet modifications alone) lost more than five percent of their initial body weight. Approximately 57 percent of orlistat users, compared to 42 percent of the placebo group, lost more than three percent of their initial body weight.

Orlistat patients also demonstrated significant decreases in total cholesterol, LDL cholesterol, systolic and diastolic blood pressure. Safety and tolerability of 60 mg orlistat in this population was similar to that observed in previous studies in a more overweight population.

"Prescription orlistat has been used successfully for years to help obese individuals lose weight and improve their health, so it's exciting to find that a lower dose of orlistat can help those who are overweight with their weight loss efforts," said lead investigator Dr. James Anderson, Professor of Medicine and Clinical Nutrition at the University of Kentucky. "The number of overweight individuals in this country continues to increase each year, and the risk of these folks progressing to obesity - and the resulting more serious med ical problems - is significant."
'"/>




Related medicine news :

1. Weight-Loss Drinks Can Make You Gassy
2. Weight-Loss Surgeries Changing Lives
3. Latest Weight-Loss Pill Offers Modest Results, Blocks Munchies
4. Weight-Loss Drugs – Will They also Make You Lose Sleep
5. What happens when Medications go wrong?
6. Medications to Prevent Relapse to Cocaine Use
7. More Elderly Take Inappropriate and Harmful Medications
8. Medications for depression
9. Medications linked to xerostomia and caries
10. Medication recuperates fat distribution in diabetes
11. Pharmacist’s Role in Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... 31, 2016 , ... Secura Consultants is sponsoring the 2016 ... 21-23 at the Spazio Westport. The conference is a three day event focused ... work primarily with physicians and professionals in the medical market. , “Professional development ...
(Date:5/31/2016)... ... May 31, 2016 , ... Joe DiMaggio Children’s ... Florida. , The clinic is led by a world class team of ... pediatric neuropsychology and also a team of certified vestibular therapists. , The ...
(Date:5/31/2016)... ... May 31, 2016 , ... Fire Door ... has joined the Fire Door Solutions’ team. Keith will serve Fire Door ... frame in-field re-labeling. He will be instrumental in developing educational curriculum and ...
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... ... using a mix of advanced Artificial Intelligence (AI) and the latest in ... The medical center is integrating predictive analytic outputs directly into the clinical workflow. ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... for June 7, 2016, to take a closer look at ... 1 p.m. ET, will focus on a man named Jay ... to wellness. The event is the first ... health care professionals, talking about triumphs and the struggles they ...
(Date:5/31/2016)... -- Mundipharma EDO GmbH (Early Development in ... trial of its investigational drug candidate EDO-S101. A first ... developed for the treatment of relapsed-refractory (RR) haematological malignances. ... safety and tolerability of ascending doses of EDO-S101 and ... the United States and Europe ...
(Date:5/31/2016)... -- , Isansys  Lifecare, a new generation digital ... wireless patient monitoring platform, as it ships more systems to ... , Scotland and Norway ... system, launched earlier this year, is now being used in ... This new technology significantly enhances the user experience and ...
Breaking Medicine Technology: